Outcome of combined liver and kidney transplantation in hepatitis C: a single-center long-term follow-up experience
Autor: | Susan Lerner, Thomas D. Schiano, Myron Schwartz, Swan N. Thung, A.C. del Pozo, Juan Del Rio Martin, Scott Ames, Kishore Iyer, Gonzalo Rodriguez-Laiz, G. de Boccardo, Mark Sturdevant, Jonathan S. Bromberg |
---|---|
Rok vydání: | 2008 |
Předmět: |
Adult
Male medicine.medical_specialty Cirrhosis Time Factors medicine.medical_treatment Biopsy Liver transplantation Gastroenterology Liver disease Hepatorenal syndrome Internal medicine medicine Humans Survivors Kidney transplantation Dialysis Aged Retrospective Studies Transplantation business.industry virus diseases Hepatitis C Middle Aged medicine.disease Kidney Transplantation digestive system diseases Surgery Liver Transplantation Survival Rate Treatment Outcome Female business Follow-Up Studies |
Zdroj: | Transplantation proceedings. 41(5) |
ISSN: | 1873-2623 |
Popis: | Introduction Hepatitis C (HCV) cirrhosis is the prevalent liver disease requiring liver transplantation in the United States. Candidates who also have end-stage renal disease, chronic renal disease stage 4, or prolonged hepatorenal syndrome are considered for combined liver and kidney transplantation (CLKT). Materials and methods We performed a retrospective study of HCV(+) and HCV(−) CLKT patients with more than 12 months of follow-up and HCV(+) patients with isolated liver transplant (OLT) to compare the outcomes of various groups. Results Since 1988, 2983 OLTs were performed at our institution including 58 CLKTs. Of these, 23 were HCV(+) subjects who were significantly older than HCV(−) CLKT patients. Race, pretransplant dialysis time, renal indication for CLKT, Model for End-stage Liver Disease score, donor age, liver and kidney rejection as well as occurrence of posttransplant hypertension were similar among HCV(+) and HCV(−) CLKT patients. Posttransplant diabetes was observed in 80% of the HCV(+) group and 30% of the HCV(−) group ( P = .01). Renal function seemed to be better in HCV(−) when compared with HCV(+) subjects at 5 years ( P = .09). Overall patient survival for HCV(+) CLKT, HCV(−) CLKT, and HCV(+) OLT groups at 1, 2, and 5 years were not significantly different ( P = .6). Conclusion HCV positivity should not exclude appropriate candidates for CLKT. |
Databáze: | OpenAIRE |
Externí odkaz: |